CDH2 and cancer: Due to the abundant evidence connecting N-cadherin and MMP2 with the invasion and metastasis of cancer, the effect of anlotinib identified in the present study indicates that progressive disease can be reduced by resistance to single-targeted anti-angiogenic drugs, as we have recently reported (40).